- Home
- AEMD vs VRAX Comparison
AEMD vs VRAX Comparison
Compare AEMD & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEMD | VRAX |
|---|---|---|
| Founded | 1984 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 1.7M |
| IPO Year | 2008 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AEMD | VRAX |
|---|---|---|
| Price | $1.69 | $0.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $287.50 | $1.00 |
| AVG Volume (30 Days) | 22.9K | ★ 191.3K |
| Earning Date | 05-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $217,274.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.31 | $0.19 |
| 52 Week High | $5.89 | $1.58 |
Technical Indicators
Market Signals| Indicator | AEMD | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 32.41 | 41.10 |
| Support Level | $1.10 | $0.20 |
| Resistance Level | $2.79 | $0.25 |
| Average True Range (ATR) | 0.12 | 0.02 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 1.12 | 27.00 |
Price Performance
Historical ComparisonAbout AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.